US stock market review for June 26

[Semiconductors take a break, "old man" stocks rebound, S&P approaches a breakdown!]

The strange tug-of-war fluctuations in big tech and semiconductors over the past few days have led to a continuous, stealthy decline in the S&P, approaching a breakdown:
A drop below 7280 would indicate a top formation and a round of correction!
Of course, if it breaks down, a subsequent pullback to 7000-7200 would be another opportunity to board the train. Friends holding VOO or QQQ can refer to this.

SOX Semiconductors
This week, performance was actually poor, down 7.94%, giving back all of last week's gains~
Moreover, the weekly chart shows clear topping signs, but the crazy speculative sentiment is still there. We're still watching the 12210 level given on Tuesday; only a break below that would weaken short-term speculative sentiment.
However, even if there is a subsequent correction, the magnitude should be controllable, not a market crash. Because Q3 earnings for the semiconductor sector will definitely still be explosive. Unless there's a slowdown in big tech spending next fiscal year as discussed yesterday, which currently seems unlikely.
Everyone should still hold onto their existing SMH and SOXX, and only average down when the price falls to the right level. Don't rush.

MU
Chip prices are putting pressure on the industry, but it's only giving back some of the post-earnings gains. The uptrend hasn't been broken; it would only weaken if it falls below 900.

NVDA
Following the drops but not the rises. It's fallen below 200, which is indeed painful to watch, and there's not much logic to it. We can only wait patiently.

MSFT
Up 5.7% today, showing a slight firmness. For now, treat it as a rebound. The rebound target is first to get back above 400, then look towards 430.

PLTR
Last year's "little man," this year's "old man." It's expected that some semiconductor stocks next year will follow this trend.
Earnings are still explosive, but it's undergoing mean reversion. A reasonable price would be below 100, at which point value investing can be considered.

LLY
A new drug for treating leukemia received EU approval, surging 7% to a new all-time high.
The current price is normal, moving slowly, target 1400.